NASDAQ:ELEV Elevation Oncology (ELEV) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free ELEV Stock Alerts $5.13 +0.12 (+2.40%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.92▼$5.2650-Day Range$2.45▼$5.1352-Week Range$0.36▼$5.89Volume438,297 shsAverage Volume3.13 million shsMarket Capitalization$249.57 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Elevation Oncology alerts: Email Address Elevation Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.3% Upside$7.25 Price TargetShort InterestBearish11.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.87) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector573rd out of 938 stocksBiological Products, Except Diagnostic Industry95th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingElevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, Elevation Oncology has a forecasted upside of 41.3% from its current price of $5.13.Amount of Analyst CoverageElevation Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.63% of the float of Elevation Oncology has been sold short.Short Interest Ratio / Days to CoverElevation Oncology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevation Oncology has recently increased by 28.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldElevation Oncology does not currently pay a dividend.Dividend GrowthElevation Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELEV. Previous Next 2.4 News and Social Media Coverage News SentimentElevation Oncology has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Elevation Oncology this week, compared to 1 article on an average week.Search Interest22 people have searched for ELEV on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elevation Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of Elevation Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Elevation Oncology are expected to grow in the coming year, from ($0.87) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevation Oncology is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevation Oncology is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevation Oncology has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Elevation Oncology Stock (NASDAQ:ELEV)Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.Read More ELEV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELEV Stock News HeadlinesMarch 28, 2024 | msn.comDesign for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist saysMarch 28, 2024 | msn.comMelanoma: All about the risks, symptoms, and common mythsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 27, 2024 | msn.comUp 825% So Far in 2024, Can This Penny Stock Go Any Higher?March 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)March 9, 2024 | benzinga.comElevation Oncology Stock (NASDAQ:ELEV), Quotes and News SummaryMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 7, 2024 | finance.yahoo.comElevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023March 6, 2024 | markets.businessinsider.comElevation Oncology, Inc. Q4 Loss decreases, beats estimatesMarch 6, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023March 6, 2024 | finance.yahoo.comElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | finance.yahoo.comElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsMarch 5, 2024 | investorplace.comTrim the Fat: 3 Overbought Stocks Poised for a PullbackMarch 4, 2024 | finance.yahoo.comElevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsMarch 2, 2024 | msn.comJMP Securities Initiates Coverage of Elevation Oncology (ELEV) with Market Outperform RecommendationMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Elevation Oncology on EO-3021’s Promising Clinical Advancements and DifferentiationFebruary 29, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the FirmFebruary 28, 2024 | finance.yahoo.comElevation Oncology to Participate in Upcoming Investor ConferencesFebruary 28, 2024 | prnewswire.comElevation Oncology to Participate in Upcoming Investor ConferencesFebruary 24, 2024 | msn.comElevation Oncology expands Phase I solid tumour trial to JapanFebruary 24, 2024 | msn.comElevation Oncology (ELEV) Price Target Increased by 31.03% to 6.46February 23, 2024 | investorplace.com3 Stock Winners That Are Up 400% or More in 2024February 22, 2024 | finance.yahoo.comElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanFebruary 22, 2024 | prnewswire.comElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanFebruary 20, 2024 | msn.comStatus Yellow Weather Warning issued for Cork and KerrySee More Headlines Receive ELEV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELEV CUSIPN/A CIK1783032 Webwww.elevationoncology.com Phone716-371-1125FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.25 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+41.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.76% Return on Assets-43.15% Debt Debt-to-Equity Ratio0.55 Current Ratio21.22 Quick Ratio21.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book3.98Miscellaneous Outstanding Shares48,650,000Free Float41,402,000Market Cap$249.57 million OptionableOptionable Beta1.34 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. David Dornan Ph.D. (Age 46)Chief Scientific Officer Comp: $545.5kMs. Valerie Malyvanh Jansen M.D. (Age 46)Ph.D., Chief Medical Officer Comp: $641.53kMr. Joseph J. Ferra Jr. (Age 49)CEO, President & Director Comp: $391.52kMs. Tammy Furlong CPAP.M.P., CFO & SecretaryMr. Ryan BloomerHead of Tech OpsCandice MasseSenior Director of Corporate Communications & Investor RelationsMr. Robert C. YangVice President of Legal AffairsMore ExecutivesKey CompetitorsX4 PharmaceuticalsNASDAQ:XFORCardiff OncologyNASDAQ:CRDFScilexNASDAQ:SCLXCompass TherapeuticsNASDAQ:CMPXGritstone bioNASDAQ:GRTSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 101,441 shares on 3/11/2024Ownership: 2.407%Vanguard Group Inc.Bought 101,441 shares on 2/15/2024Ownership: 2.761%Citadel Advisors LLCSold 248,718 shares on 2/15/2024Ownership: 1.395%View All Institutional Transactions ELEV Stock Analysis - Frequently Asked Questions Should I buy or sell Elevation Oncology stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELEV shares. View ELEV analyst ratings or view top-rated stocks. What is Elevation Oncology's stock price target for 2024? 5 analysts have issued 12 month target prices for Elevation Oncology's stock. Their ELEV share price targets range from $6.00 to $8.00. On average, they expect the company's share price to reach $7.25 in the next twelve months. This suggests a possible upside of 41.3% from the stock's current price. View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts. How have ELEV shares performed in 2024? Elevation Oncology's stock was trading at $0.5370 at the beginning of the year. Since then, ELEV shares have increased by 855.3% and is now trading at $5.13. View the best growth stocks for 2024 here. Are investors shorting Elevation Oncology? Elevation Oncology saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,630,000 shares, an increase of 28.3% from the February 29th total of 3,610,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the shares of the company are sold short. View Elevation Oncology's Short Interest. When is Elevation Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ELEV earnings forecast. How were Elevation Oncology's earnings last quarter? Elevation Oncology, Inc. (NASDAQ:ELEV) announced its earnings results on Wednesday, March, 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02. When did Elevation Oncology IPO? Elevation Oncology (ELEV) raised $1 billion in an IPO on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share. Who are Elevation Oncology's major shareholders? Elevation Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.41%), Vanguard Group Inc. (2.76%) and Citadel Advisors LLC (1.39%). Insiders that own company stock include Global Hc Fund Pte Vertex II, Global Strategic Fund I Venbio and Yun-Lung Chen. View institutional ownership trends. How do I buy shares of Elevation Oncology? Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELEV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.